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7The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, USA; and 8Philips Healthcare, Madrid, Spain
Received 15 April 2020; revised 2 June 2020; editorial decision 17 June 2020; accepted 19 June 2020; online publish-ahead-of-print 29 June 2020
Aims Anthracycline-induced cardiotoxicity (AIC) is a serious adverse effect among cancer patients. A central mechanism of AIC




Forty Large-White pigs were included. In Study 1, 20 pigs were randomized 1:1 to remote ischaemic precondition-
ing (RIPC, 3 cycles of 5 min leg ischaemia followed by 5 min reperfusion) or no pretreatment. RIPC was performed
immediately before each intracoronary doxorubicin injections (0.45 mg/kg) given at Weeks 0, 2, 4, 6, and 8. A group
of 10 pigs with no exposure to doxorubicin served as healthy controls. Pigs underwent serial cardiac magnetic reso-
nance (CMR) exams at baseline and at Weeks 6, 8, 12, and 16, being sacrifice after that. In Study 2, 10 new pigs re-
ceived 3 doxorubicin injections (with/out preceding RIPC) and were sacrificed at week 6. In Study 1, left ventricular
ejection fraction (LVEF) depression was blunted animals receiving RIPC before doxorubicin (RIPC-Doxo), which
had a significantly higher LVEF at Week 16 than doxorubicin treated pigs that received no pretreatment
(Untreated-Doxo) (41.5 ± 9.1% vs. 32.5 ± 8.7%, P = 0.04). It was mainly due to conserved regional contractile func-
tion. In Study 2, transmission electron microscopy (TEM) at Week 6 showed fragmented mitochondria with severe
morphological abnormalities in Untreated-Doxo pigs, together with upregulation of fission and autophagy proteins.
At the end of the 16-week Study 1 protocol, TEM revealed overt mitochondrial fragmentation with structural frag-
mentation in Untreated-Doxo pigs, whereas interstitial fibrosis was less severe in RIPCþDoxo pigs.
....................................................................................................................................................................................................
Conclusion In a translatable large-animal model of AIC, RIPC applied immediately before each doxorubicin injection resulted in
preserved cardiac contractility with significantly higher long-term LVEF and less cardiac fibrosis. RIPC prevented mi-
tochondrial fragmentation and dysregulated autophagy from AIC early stages. RIPC is a promising intervention for
testing in clinical trials in AIC.
                                                                                                                                                                                                                   
*Corresponding author. Tel: þ34 914 53 12 00 (ext.4302), E-mail: bibanez@cnic.es
VC The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which per-
mits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact
journals.permissions@oup.com









































Keywords Cardiotoxicity • Anthracyclines • Cardio-oncology • Remote conditioning • Mitochondria • Magnetic
resonance imaging
1. Introduction
Anthracyclines, used alone or in combination with other approaches, re-
main the first line therapy for many forms of cancer. Anthracycline-
induced cardiotoxicity (AIC) is a well-known side effect of these agents,
limiting the total lifetime cumulative dose a patient can receive.1 The
mechanisms by which anthracyclines generate cardiotoxicity seem to
converge on damage to mitochondria.2
Several definitions of cardiotoxicity have been proposed, with a con-
sensus conception of cancer therapy-related cardiac dysfunction as a re-
duction in left ventricular ejection fraction (LVEF) of 10 absolute points
to a value below the normal range for the imaging technique.3–6 Severe
AIC is associated with chronic heart failure (HF), which translates into in-
creased mortality.6
Current treatment strategies for established AIC include standard HF
therapies (beta-blockers and ACEs inhibitors, among others). Early inter-
vention with these therapies is of limited effect, providing partial recov-
ery of cardiac function in only some patients.7 With the exception of
dexrazoxane, which reduced cardiac injury in a paediatric population,8
specific therapies able to prevent the development of AIC are lacking.8–10
Given the central role of mitochondria in AIC, several interventions
targeting mitochondrial processes have been tested, including antioxi-
dants, iron chelators, and cell therapy; however, despite promising pre-
clinical results, these approaches have failed to demonstrate a clinical
benefit.11
Remote ischaemic conditioning is the process whereby brief, revers-
ible episodes of ischaemia and reperfusion in one vascular bed (e.g. an
arm) confers a global protection that renders remote tissues and organs
resistant to injury.12 In the context of ischaemia/reperfusion injury (acute
myocardial infarction), remote ischaemic conditioning has been consis-
tently associated with cardioprotection.13 A central mechanism underly-
ing the benefits of remote ischaemic conditioning is mitochondrial
protection.12 Conditioning before the index injury [remote ischemic
PREconditioning (RIPC)]14 has been shown to be very effective; how-
ever, initiation of conditioning during the index injury (remote ischaemic
PERconditioning) confers a weaker protection.15 Nevertheless, anthra-
cycline administration is a fully controlled and programmed
intervention, and the cardiac injury event is thus predictable. Therefore,
given the central role of mitochondrial damage in AIC, RIPC seems a
good candidate therapy for testing in this context. In this study, we tested
RIPC as a cardioprotective strategy in a validated large-animal model of
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..AIC induced by serial intracoronary administrations of doxorubicin.16
The intracoronary approach offers the advantage of avoiding the myelo-
suppressive adverse effects of systemic administration of higher doses of
anthracyclines that severely compromises long-term large-animal stud-
ies. Monitoring by cardiac magnetic resonance (CMR) revealed that
the severe cardiac dysfunction associated with serial intracoronary
doxorubicin administration is significantly attenuated by RIPC applied
immediately before each anthracycline administration. RIPC prevented




All animal studies were conducted at the CNIC and approved by the lo-
cal CNIC Institutional and regional animal research committees. All ani-
mal procedures conformed to EU Directive 2010/63EU and
Recommendation 2007/526/EC regarding the protection of animals
used for experimental and other scientific purposes.
The study design is summarized in Figure 1. In Study 1, we tested the
efficacy of RIPC in a model of overt AIC with long-term evaluation: 20
Large-White male pigs (3 months old, weighting 30 kg) received a se-
ries of 5 intracoronary doxorubicin injections in order to induce severe
AIC.16 The 0.45 mg/kg injections were spaced 2 weeks apart (Weeks 0,
2, 4, 6, and 8). Before commencing injections, animals were randomized
1:1 to RIPC or no pretreatment. There were thus two AIC treatment
groups: those with preconditioning (RIPC-Doxo) and those with no pre-
treatment (Untreated-Doxo). RIPC consisted on 3 cycles of 5 min lower
limb ischaemia followed by 5 min reperfusion before each doxorubicin
injection. All pigs underwent serial CMR exams at Weeks 0, 6, 8, 12, and
16. After the 16-week CMR exam, animals were sacrificed, and cardiac
tissue was harvested for histology, transmission electron microscopy
(TEM), and protein expression analysis. Another group of 10 pigs with
no exposure to doxorubicin served as healthy controls.
In Study 2, 10 new pigs (randomized to RIPC or no treatment) were
administrated with only 3 doxorubicin intracoronary injections, a ‘sub-
clinical’ protocol associated with preserved cardiac function.16 The
RIPC-Doxo and Untreated-Doxo pigs in Study 2 underwent CMR
exams at Weeks 0 and 6. After the 6-week CMR exam, pigs were sacri-
ficed and cardiac tissue harvested for histology, TEM, and protein ex-
pression analysis.
2.2 Remote ischaemic preconditioning
RIPC was induced under general anaesthesia (20 mg/kg of ketamine,
2 mg/kg of xylazine, and 0.5 mg/kg of midazolam by intramuscularily injec-
tion) by securing a tourniquet around the right hind leg to produce tran-
sient ischaemia. Total ischaemia was assured by checking visually for the
congestive reaction in the lower extremity and by Doppler echography
in the inner side of the thigh, pressing the tourniquet until artery flow
Figure 1 Study design. Study 1 consisted of 30 castrated Large-White male pigs; 20 pigs were randomized the AIC protocol with no pretreatment
(Untreated-Doxo) or preceded at each cycle by RIPC (RIPC-Doxo). An additional 10 animals were monitored as healthy controls. CMR scans were per-
formed at baseline (Week 0) and at 6, 8, 12, and 16 weeks. Animals were sacrificed, and hearts were excised for ex vivo analysis. Study 2 consisted of 10
animals randomized to Untreated-Doxo or RIPC-Doxo and sacrificed 2 weeks after the third doxorubicin dose. CMR scans were performed at baseline
(Week 0) and at 6 weeks.

































































































ceased. Each of the three RIPC cycles consisted of 5 min of total ischae-
mia followed by 5 min of reperfusion. The initiation of doxorubicin intra-
coronary injection was approximately 10 min after the end of the third
conditioning cycle.
2.3 Intracoronary doxorubicin injection
Doxorubicin was administered according to a previously detailed proto-
col.16 In brief, animals were anaesthetized (20 mg/kg of ketamine, 2 mg/
kg of xylazine, and 0.5 mg/kg of midazolam by intramuscularily injection)
and maintained with intravenously perfusion of the same anaesthetics
cocktail (per hour) they were also endotracheally intubated.
Intramuscular buprenorphine (0.01 mg/kg) was also intramuscular ad-
ministrated before the catheterism. The right femoral artery was then
repeatedly accessed in each catheterization by the Seldinger technique,
and a 5-Fr sheath was inserted. Pigs were anticoagulated with 150 IU/kg
of intravenous heparin, and a 4-Fr coronary diagnostic catheter was
inserted via a femoral sheath and placed at the origin of the left coronary
artery. Under angiography guidance, a 0.014 mm coronary guide wire
was positioned distally in the left anterior descending (LAD) coronary
artery. The catheter was docked selectively in the proximal LAD, and a
0.45 mg/kg dose of doxorubicin (FarmiblastinaVR , Pfizer) diluted in 30 mL
saline was given as a slow bolus injection over 3 min.
Electrocardiographic and haemodynamic parameters were monitored
during doxorubicin administration. Once infusion was complete, normal
coronary flow was documented by coronary angiography, the material
was removed, and the animal was allowed to recover.
2.4 CMR imaging
All studies were performed with a Philips 3-T Achieva Tx whole body
scanner (Philips Healthcare, Best, The Netherlands) equipped with a 32-
element phased-array cardiac coil. The CMR protocol included a stan-
dard segmented cine steady-state free-precession (SSFP) sequence to
provide high-quality anatomical references, T1-mapping, and T1W late
gadolinium enhancement (LGE) sequences. The imaging parameters for
the cine SSFP sequence were as follows: field of view (FOV), 280 mm 
280 mm; slice thickness, 6 mm with no gaps; repetition time (TR), 2.8 ms,
echo time (TE), 1.4 ms; flip angle, 45; cardiac phases, 30; voxel size, 1.8
mm  1.8 mm; and number of excitations, 3. The T1-mapping sequence
(Modified Look-Locker Inversion recovery) was based on a 5(3)3
scheme using a single-shot SSFP readout sequence (TR/TE/flip angle =
2.1 ms/1.05 ms/350) with an in-plane acquisition resolution of 1.5 1.8
mm2 and an 8 mm slice thickness. The T1 mapping sequence was trig-
gered at mid-diastole and acquired from a single short-axis mid-apical
slice. LGE imaging was performed 15 min after intravenous administra-
tion of 0.2 mM/kg gadopentetate dimeglumine contrast agent using an
3D inversion recovery spoiled turbo field echo sequence (TR/TE/flip an-
gle = 2.4 ms/1.13 ms/100) with an isotropic resolution of 1.5 1.5 1.5
mm3 on a FOV of 340 340 320 mm3 in the foot-head (FH), left-right
(LR), and anterior-posterior (AP) directions. Data were acquired in mid-
diastole with a 151.2 ms acquisition window. Acquisition was accelerated
using a net SENSE factor of 2.25 (1.5 1.5 in the AP and LR directions)
with a bandwidth of 853 Hz per pixel. Inversion time was adjusted before
acquisition using a look-locker scout sequence with different inversion
times to ensure proper nulling of the healthy myocardium signal. For the
analysis, 3D volume was reconstructed in short axis, two chamber, and
four chamber views with a slice thickness of 6 mm.
2.5 Image analysis
CMR studies were analysed by an experienced observer and reviewed
by a blinded experienced independent observer using dedicated soft-
ware (IntelliSpace Portal, Philips Healthcare, Best, the Netherlands). LV
cardiac borders were traced in each cine image to obtain LV
end-diastolic mass, LV end-diastolic volume (LVEDV), end-systolic vol-
ume (LVESV), and LVEF. Wall thickening values for the assessment of in-
fused (LV region supplied by the LAD) and remote contractile function
were also obtained by tracing cardiac borders in systole and diastole. T1
maps were generated by using a maximum-likelihood expectation–maxi-
mization algorithm and fitting the MR signal to a T1 inversion recovery
with three independent model parameters. T1 relaxation maps were
quantitatively analysed by placing a wide transmural region of interest at
the infused myocardial area (irrigated by the LAD) of the corresponding
slice in all studies.
2.6 Ex vivo analysis
After sacrifice by intravenous injection of pentobarbital in overdose
(50 mg/kg intravenously), samples of the doxorubicin-infused region (an-
terior wall) and the remote area (posterior wall) were collected for his-
tology, TEM, and protein expression analysis. For histology, samples
were fixed in 4% formalin and embedded in paraffin, and 4-lm sections
were cut and stained with haematoxylin and eosin, Masson trichrome,
and Sirius Red. Sirius Red sections were scanned, and 20 20 magnifica-
tion images were captured for collagen quantification using a modified
macro.17
2.7 Transmission electron microscopy
Samples from the infused area were maintained in 4% glutaraldehyde in
10% paraformaldehyde for 24–48 h. Tissues were then post-fixed in 1%
osmium tetroxide in water for 1 h at room temperature. Samples were
washed with water and block-stained with 0.5% uracil acetate in water
for 10 min. Samples were then dehydrated through a series of aqueous
alcohol solutions (30%, 50%, 70%, 95%, and 100%) and a final passage
through acetone. After this, samples were included in Durcupan epoxy
resin through increasing resin:acetone mixtures (1:3 then 3:1) and, finally,
pure resin. Resin-included samples were polymerized in an oven at 60C
for 48 h. Ultrathin (60 nm) slices were cut with a Leica Ultracut S ultrami-
crotome and were deposited on 200 mesh copper grids. Grids were
counterstained with uranyl acetate and lead citrate. Images were
obtained with a Jeol Jem1010 (100 kV) transmission electron micro-
scope linked to a Gatan camera (Orius 200 SC model); acquired images
were processed with Digital Micrograph software. Individual images
were acquired using ImageJ software (1.52p Wayne Rasband from the
US National Institutes of Health) at the following magnifications: 6000
for tissue evaluation, 10 000 for mitochondrial quantification (10
images with a total of7440lm2 of myocardium extension and a mean
of 250 mitochondria per animal), and 40 000 for the assessment of
mitochondrial cristae.
2.8 Western blotting
Heart tissue from infused area was lysed in Radioimmunoprecipitation
assay (RIPA) buffer supplemented with a protease and phosphatase in-
hibitor cocktail. Protein content was quantified with the Bio-Rad
Bicinchoninic acid (BCA) protein assay. Protein samples were separated
by sodium dodecyl sulfate (SDS)–polyacrylamide gel electrophoresis,
and proteins were transferred to nitrocellulose membranes. After block-
ing, membranes were incubated with the following antibodies: BECLIN1

































































































(Cell Signaling, 3738S), p62 (Cell Signaling, 5114S), DRP1 (Cell Signaling,
8570S), and GAPDH (Abcam, ab8245) at 4C overnight. Bound antibod-
ies were detected after staining with a corresponding secondary anti-
body. Quantitative densitometric analysis was performed using ImageJ
Fiji software.
2.9 mtDNA quantification
mtDNA was quantified by quantitative real-time polymerase chain
reaction (PCR) using SYBR Green, and mtDNA content was presented
as the ratio of mitochondria-encoded 16S to nuclear-encoded HPRT.
16S primers: forward 5-CGATGTTGGATCAGGACACC-3, reverse 5-




According to the data distribution, continuous variables were calculated
as mean ± standard deviation (SD) or median ± interquartile range
(IQR). In text, data are reported as mean ± SD, while in the main figure,
data are reported as mean ± standard error (SE) for better visual
interpretation. Data normality was assessed with the Shapiro–Wilk test.
Cardiac mass and volume data were indexed by body weight using the
modified Brody formula. Differences were considered statistically signifi-
cant at P < 0.05. All data were analysed with RStudio [RStudio Team
(2015): Integrated Development for RStudio, Inc., Boston, MA, USA],
and graphics were created with ggplot2.
Sample size in each treatment group (RIPC-Doxo and Untreated-
Doxo) was calculated in order to detect an 8% between-group differ-
ence in LVEF at 16-week CMR (study primary endpoint) with an SD of
6.5%, no casualties (previously defined in the animal model16) a power of
0.8, and 0.05 of bilateral significance. The primary endpoint is similar to
that in other cardioprotection studies, and the sample size calculation
resulted in 10 animals per group. Two-group comparisons were by t-
test, taking account of RIPC exposure at the end of the study (16 weeks).
Comparisons over time within each group for all the CMR data were
made by repeated one-way analysis of variance (ANOVA) measure-
ments with Bonferroni correction.
3. Results
During doxorubicin injections, none of the pigs showed adverse events
(changes in electrocardiogram -ECG- or systolic arterial pressure). One
pig randomized to RIPC died immediately after the third anthracycline in-
jection due to a complication related to the invasive procedure and was
replaced to maintain the pre-specified sample size. Another pig from
Untreated-Doxo group died after the final CMR exam at 16 weeks, we
decided not to use ex vivo samples for water quantification and TEM/WB
from this animal.
3.1 RIPC prevents anthracycline-induced
cardiac dysfunction
The series of five doxorubicin injections in Study 1 caused a progressive
deterioration of LV systolic function in pigs allocated to the non-RIPC
AIC group (Untreated-Doxo). LVEF remained unchanged until the
fourth doxorubicin injection. From there on, LVEF progressively deterio-
rated to the end of the study. LV systolic function deterioration was sig-
nificantly blunted in pigs receiving RIPC before each doxorubicin
injection (RIPC-Doxo group) (Figure 2). LVEF at Week 16 (primary study
endpoint) was significantly higher in the RIPC-Doxo group (41.5% ±
9.1% and 32.5% ± 8.7% for RIPC-Doxo vs. Untreated-Doxo; P = 0.04).
Cardiac dysfunction was already overt at Week 12 CMR (LVEF = 43.2%
± 8.1% and 33.4% ± 9.1% in RIPC-Doxo vs. Untreated-Doxo; P = 0.02)
(Figure 2A). There was no between-group difference in 16-week LVEDV
(156.0 ± 38.4 mL and 168.0 ± 69.7 mL in RIPC-Doxo vs. Untreated-
Doxo; p = 0.63), whereas LVESV was non-significantly lower in the RIPC
group (93.1 ± 35.2 mL and 118.0 ± 64.3 mL in RIPC-Doxo vs. Untreated-
Doxo; P = 0.30) (Supplementary material online, Figure S1). All CMR data
from Study 1 are detailed in Supplementary material online, Table S1.
More preserved LVEF after RIPC could be due to preserved contrac-
tile function in the doxorubicin-infused region or to a compensatory
contractile function effect in the remote area. To test these possibilities,
we measured wall thickening as an index of contractility in the infused
and remote LV regions (Figure 2B). RIPC was associated with a significant
contractile improvement only in the infused region (23.8% ± 15.2% and
6.59% ± 11.4% in RIPC-Doxo vs. Untreated-Doxo; P = 0.01, Figure 2B).
Remote myocardium contractility did not differ significantly between
groups (58.4% ± 28.1% vs. 45.4% ± 21.0% in RIPC-Doxo vs. Untreated-
Doxo; P = 0.26) (Supplementary material online, Figure S2).
Figure 2 Functional CMR in Study 1. (A) LVEF over time (left) and at
16 weeks (right). Grouped data are presented as mean ± SE and individ-
ual data at the end of the study as a dotplot. N = 10 animals per group.
The significance of differences between Untreated-Doxo and RIPC-
Doxo groups at 16 weeks was assessed by the Student’s t-test. (B) Wall
thickening at 16 weeks in the doxorubicin-infused area (mean of the
AHA segments 7 and 8). Grouped data are presented as mean ± SE
and individual data at the end of the study as a dotplot. N = 10 animals
per group. The significance of differences between Untreated-Doxo
and RIPC-Doxo at 16 weeks was assessed by the Student’s t-test.

























































..3.2 RIPC reduces myocardial fibrosis
associated with anthracycline-induced
cardiotoxicity
Myocardial tissue changes were evaluated in vivo by serial T1 mapping
evaluations and ex vivo in samples harvested at the end of the 16-week
protocol. T1 relaxation times increased from baseline to Week 16 in
both treatment groups. In the RIPC-Doxo group, baseline T1 was
1150± 58 ms and increased to 1300± 109 ms at Week 16 (P = 0.03). In
the Untreated-Doxo group, T1 increased from 1110 ± 63 ms at baseline
to 1410± 108 ms at 16 weeks (P = 0.01). The increase in T1 relaxation
time was significantly smaller in the RIPC group (11.0 ± 8.58% and
20.3± 10.3% in RIPC-Doxo vs. Untreated-Doxo; P = 0.04) (Figure 3A).
Correlated with the CMR data, Sirius Red staining at the end of the study
revealed a significantly smaller collagen area in the RIPC group (16.9% ±
5.4% and 24.4% ± 9.6% in RIPC-Doxo vs. Untreated-Doxo; P = 0.04)
(Figure 3B).
3.3 RIPC attenuates mitochondrial
fragmentation in end-stage anthracycline-
induced cardiotoxicity
TEM evaluation of myocardial samples obtained at Week 16 revealed
massive mitochondrial fragmentation in non-RIPC pigs (median ± IQR
mitochondrial size 0.31 ± 0.30lm2 and 0.17± 0.15 lm2 for healthy con-
trols vs. Untreated-Doxo pigs; P < 0.001). Fragmentation was less severe
in pigs undergoing RIPC before each doxorubicin injection
(0.20± 0.2lm2 and 0.17± 0.15 lm2 for RIPC-Doxo vs. Untreated-
Doxo; P < 0.001). Area distribution analysis confirmed that the size dis-
tribution of mitochondria in RIPC-Doxo pigs was between that of con-
trols and animals (Figure 4A,B). In addition to the differences in
mitochondria size, the Untreated-Doxo animals had elongated and aber-
rantly shape mitochondria, likely as a result of fragmentation; these, with
massive loss of cristae and electrodense aggregates due to the subse-
quent cristae rupture (Figure 4C).
3.4 RIPC prevents disruption of
mitochondrial dynamics and dysregulated
autophagy occurring early in the course of
AIC
We next examined mitochondrial dynamics and other processes associ-
ated with cell damage during the subclinical stages of AIC, when cardiac
function was still unaffected. For this, we included a new group of 10 pigs
(Study 2) that received only three doxorubicin injections; as before, the
pigs were first randomized to RIPC or no pretreatment (N = 5 per arm).
Pigs were sacrificed at Week 6 (2 weeks after the third doxorubicin in-
jection). CMR performed immediately before sacrifice revealed normal
LVEF in both groups (57.7% ± 2.08% and 55.3% ± 5.16% in the RIPC-
Doxo and Untreated-Doxo groups vs. 64.1± 6.24% in healthy controls).
LV volumes and LV mass were also unaffected (Supplementary material
online, Table S2).
Despite normal heart function, Untreated-Doxo pigs at this early
stage of doxorubicin exposure had severe alterations in mitochondrial
morphology, with a clear fragmented phenotype (median ± IQR mito-
chondrial size = 0.27 ± 0.34 lm2 in Untreated-Doxo pigs vs.
0.308± 0.30 lm2 in healthy controls; P < 0.001). This fragmented pheno-
type was not present in myocardial mitochondria from RIPC-Doxo pigs,
and mitochondria in this group were significantly larger than in
Untreated-Doxo pigs (0.34 ± 0.31 lm2 vs. 0.27± 0.34 lm2 for RIPC-
Doxo vs. Untreated-Doxo; P < 0.001) (Figure 5A). The area distribution
curve for RIPC-Doxo pigs superimposed that of healthy controls,
whereas Untreated-Doxo pigs showed a more fragmented distribution
(Figure 5B). Irregularly shaped, small, and fragmented mitochondria sur-
rounded by ribosomes were found in Untreated-Doxo pigs receiving
only three doxorubicin injections (Study 2). The morphology of mito-
chondria from RIPC-Doxo pigs in Study 2 presented some disruption of
Figure 3 CMR and histology analysis of cardiac tissue. (A) Native T1 differential at the end of the study (16 weeks – baseline) (right). Grouped data are
presented as mean ± SE and individual data at the end of study as a dotplot. N = 10 animals per group. The significance of differences between Untreated-
Doxo and RIPC-Doxo groups at 16 weeks was assessed by the Student’s t-test. (B) Collagen fraction area at 16 weeks. Samples were obtained from the
medium antero-septal region. Data are presented grouped in a boxplot and ungrouped (individual data) as a dotplot. N = 10 animals per group. Shaded
grey lines represented mean and standard deviation of the collagen data from Healthy Control group. The significance of differences between Untreated-
Doxo and RIPC-Doxo at 16 weeks was assessed by the Student’s t-test. (C) Representative histology images illustrating myocardial interstitial fibrosis (SR
and Masson’s trichrome) at 16 weeks.
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Figure 4 TEM analysis of myocardial mitochondria after 16 weeks of AIC (Study 1). (A) Individual mitochondrial area in the infused area in each animal
group (dotplot) with its boxplot and violin plot related distribution. (B) Distribution of mitochondrial density vs. mitochondrial area in each animal group.
(C) Representative TEM images at 6000 and 40 000 showing cardiac mitochondria replicates for each animal group. N = 5 animals per group. Data
were analysed by linear regression nested according to treatment group and animal ID (Untreated-Doxo and RIPC-Doxo).



























































..cristae but conservation of shape and size (Figure 5C). Western blot
analysis revealed that the mitochondrial fragmentation in Untreated-
Doxo pigs was associated with a significant upregulation of the fission
master regulator dynamin-related protein-1 (DRP1) (Figure 6A,C).
Doxorubicin-induced DRP-1 upregulation was blocked RIPC
(Figure 6A,C). mtDNA quantification confirmed the fragmented mito-
chondrial phenotype of Untreated-Doxo pigs, which had more mtDNA
copies than RIPC-Doxo pigs and healthy controls (Figure 6B). Given the
role of mitochondrial dysfunction in autophagy dysregulation and the im-
pact on the latter on cardiac function, we next explored the impact of
disrupted mitochondrial dynamics on the autophagy machinery.
Expression of the autophagy-related proteins Beclin 1 and p62 was signif-
icantly higher in Untreated-Doxo pigs than in RIPC-Doxo pigs receiving
doxorubicin and healthy controls (Figure 6D,E). Original WB unedited
gels are detailed in Supplementary material online, Figure S3.
4. Discussion
In this study, we tested the cardioprotective effect of RIPC before doxo-
rubicin administration in a large-animal model of AIC. Long-term serial
CMR evaluation showed that RIPC significantly attenuates cardiac dys-
function associated with AIC. Hearts from RIPC-treated animals had sig-
nificantly less myocardial fibrosis. Doxorubicin caused significant
mitochondrial damage from the early stages after administration: at sub-
clinical AIC stages (before overt cardiac dysfunction), doxorubicin in-
duced a severe fragmented mitochondria phenotype and upregulated
autophagy markers. RIPC applied before doxorubicin injections pre-
vented the mitochondrial morphological abnormalities and the disrup-
tion of mitochondrial dynamics. These data identify RIPC as a potential
cardioprotective strategy to prevent AIC and support the translation of
this therapeutic strategy to the clinic.
Anthracyclines have been in clinical use for more than 50 years and,
alone or in combination with other agents, remain the first line therapy
for many cancer types. AIC is one of the most feared side effects of these
efficacious chemotherapy agents. Most recent data show that up to 30%
of patients treated with anthracyclines develop some degree of cardio-
toxicity, and AIC manifests as significant cardiac dysfunction in up to 10%
of patients.3,6 Severe AIC is more frequent among especially vulnerable
populations, such as the elderly. The unavoidable trade-off between can-
cer and chronic HF places a major burden on individuals and healthcare
systems.
The current approach to AIC includes early detection by serial imaging
and the use of non-specific HF therapies such as beta-blockers or ACE-
inhibitors.4,18 However, even when these are initiated early after AIC di-
agnosis, recovery cardiac function is usually incomplete.7 Currently, the
only FDA-approved drug for the prevention of AIC is dexrazoxane, an
iron chelator that has been shown to reduce myocardial injury in a paedi-
atric population.8,19 However, dexrazoxane is not used in daily practice,
and its efficacy for AIC prevention in adults is uncertain; more clinical tri-
als are needed to clearly define its cardioprotective effect.20 Moreover,
most recent clinical trials with ACE-inhibitors or beta-blockers showed
inconsistent reductions in AIC.21–23 There is therefore a clinical need to
identify effective preventive therapies for AIC.
Remote ischaemic conditioning has been extensively validated in ex-
perimental studies12,13 and early clinical trials24 as an intervention able to
ameliorate cardiac damage associated with acute myocardial infarction
(AMI). The protective effect of remote conditioning is stronger when it is
applied before the index episode (PREconditioning); unfortunately, is-
chaemia onset in AMI is an unpredictable event, and remote conditioning
in this context is therefore only feasible during ongoing infarction
(PERconditioning).12 Despite promising results from RIC-STEMI trial,25 in
the largest clinical trial in AMI patients, the CONDI-2/ERIC-PPCI trial, re-
mote ischaemic perconditioning did not improve clinical outcomes.15
Unlike AMI, anthracycline administration is a fully programmed event,
and it is thus possible to schedule RIPC. The positive results reported
here and the ease of implementing this strategy in the clinic identify RIPC
as a strong candidate for testing in future clinical trials. The safety of RIPC
demonstrated in many trials in AMI add to the attraction of this strategy.
Figure 5 TEM analysis of myocardial mitochondria after 6 weeks of AIC (Study 2). (A) Individual mitochondrial area in the infused area in each animal
group (dotplot) with its boxplot and violin plot related distribution. (B) Distribution of mitochondrial density vs. mitochondrial area in each animal group.
(C) Representative TEM images at 6000 and 40 000 showing all cardiac mitochondria replicates for each animal group. N = 5 animals per group. Data
were analysed by linear regression nested according to treatment group and animal ID (Untreated-Doxo and RIPC-Doxo). The red arrowhead indicates
a fragmented mitochondria and the blue arrowhead a secondary lysosome.




















.Ischaemic conditioning has scarcely been tested in the context of AIC.
Schjøtt et al.26 tested ischaemic preconditioning in isolated rat hearts be-
fore epirubicin administration; local ischaemic preconditioning of
explanted hearts was associated with an attenuation of epirubicin-
induced cardiac dysfunction. More recently, Maulik et al.27 tested ischae-
mic preconditioning in cultured cardiomyocytes exposed to doxorubi-
cin. Supporting the ex vivo data,26 their results showed that
cardiomyocytes subjected to ischaemic preconditioning were protected
against doxorubicin-induced cell death.27
Importantly, ischaemic preconditioning in these studies did not
impact a competitive advantage to cancer cells exposed to
doxorubicin, providing an additional safety benefit to this strategy. Very
recently, Gertz et al.28 published the first in vivo evidence of the cardio-
protection afforded by RIPC in a mouse model of AIC. RIPC was associ-
ated with improved survival and attenuated cardiac fibrosis
and autophagy. However, the anthracycline regime in that study did im-
pact cardiac function, and thus the cardioprotective effect of RIPC
was less clear.28 In line with the Gertz et al. study,28 our results in pigs
Figure 6 Myocardial mitochondria protein expression in the infused area after 6 weeks of AIC (Study 2). (A) Western blot analysis of the myocardial
expression of Beclin1, p62, and DRP1 in all animals. (B) Myocardial mitochondrial DNA content. (C–E) Quantification of protein expression (fold-in-
creased, normalized to GAPDH) for (C) DRP1, (D) Beclin 1, and (E) p62. (n = 4 in Healthy controls, 5 in Untreated-Doxo, and 5 in RIPC-Doxo groups).
Significance differences between groups were calculating using one-way ANOVA.

































































































show that RIPC triggers a significant reduction in the cardiac expression
of key autophagy factors.
Despite of the lack of experimental evidence from animal studies to
support the ability of RIPC to prevent AIC, two small clinical trials are
ongoing. Chung et al.29 (NCT02471885) are testing a series of four RIPC
cycles (5 min each) in the arm before each chemotherapy cycle in a pop-
ulation of 128 patients receiving anthracyclines for various types of can-
cer. In another trial (NCT03166813), Li et al. are testing a different RIPC
protocol (three cycles of 5 min) applied either in the arm or in the leg be-
fore each chemotherapy cycle in a paediatric population (4–18 years
old) receiving anthracyclines. Both trials have high-sensitivity cardiac tro-
ponin T (hs-cTnT) after the end of chemotherapy as the primary
endpoint.
Our study provides the first demonstration that RIPC protects the
heart against AIC in a large-animal model. Unlike the results from mice,28
in our model, anthracyclines had a clear cardiocytotoxic effect, and we
were able to detect differences in cardiac function and cardiac contrac-
tile function between animals receiving RIPC or no pretreatment. We
also found differences in T1 mapping values implicated in AIC.30 In agree-
ment with the results from mice,28 at the end of the study protocol we
found that RIPC-treated animals had significantly less fibrosis (collagen
fraction) that animals receiving no pretreatment.
The mechanism by which RIPC exerts its cardioprotective effect
against AIC is incompletely understood. There is evidence identifying
neuronal and humoral mediators that transfer the protective signal from
the periphery (e.g. the leg undergoing brief intermittent ischaemia epi-
sodes) to the heart.31 At the heart’s level, there is firm evidence that mi-
tochondrial damage plays a central role in AIC2,.32,33 To investigate the
mechanism of protection, we therefore explored mitochondrial dynam-
ics (fusion/fission) and authophagy.34 Our TEM analysis revealed that mi-
tochondria from doxorubicin-injected pigs not undergoing RIPC were
abnormally small, had irregular and aberrant morphology, and contained
a hyper-dense matrix, confirming previous reports.32,35 Morphological
abnormalities were present very early in course of AIC (before overt
cardiac dysfunction) and progressed to an extreme phenotype by the
end of the 16-week protocol. RIPC prevented most of these morpholog-
ical abnormalities from early in the course of AIC. Confirming these find-
ings, protein expression of the mitochondrial fission master regulator
DRP-1 was upregulated by doxorubicin treatment and normalized by
RIPC, as was autophagy, evaluated early in the course of AIC by the ex-
pression of Beclin-1 and p62. Although autophagy is essentially protec-
tive and not a deleterious process (at least in the context of myocardial
infarction),36 when dysregulated it can lead to cell death.37
Mitochondrial morphology abnormalities have emerged as essential trig-
ger of autophagy. We propose that the severe mitochondrial dysfunc-
tion triggered by doxorubicin exposure induces a dysregulated
autophagy in cardiomyocytes that leads to subsequent heart dysfunction.
RIPC, by preserving mitochondrial integrity during AIC, halts this process
and results in a long-term cardiac protection (Graphical Abstract).
In conclusion, this study provides evidence of the efficacy of RIPC in
preventing AIC in a translational large-animal model. RIPC-mediated car-
dioprotection starts early in the course of AIC, in the subclinical phase,
and has important downstream benefits on cardiac function. Our study
supports the execution of adequately powered well-designed clinical tri-
als to confirm this benefit in the clinical setting.
4.1 Study limitations
The intracoronary route for doxorubicin injection used here does not
mimic the clinical scenario and is a highly aggressive model. We16 and
others38,39 have used this administration route in the past as a means of
avoiding the myelosuppression associated with systemic doxorubicin in-
jection, which is pronounced in pigs.40 Nevertheless, the protective ef-
fect of RIPC in this extreme model strongly supports its translational
potential. A further limitation in this study is the use of healthy juvenile
pigs, which are free of the comorbidities frequent in cancer patients de-
veloping AIC, many of whom are elderly. In this study, we have not evalu-
ated the expression of some pro-survival signals, such as STAT-3, known
to be upregulated by after RIPC in the context of myocardial
infarction.41,42
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25. Gaspar A, Lourenço AP, Pereira MÁ, Azevedo P, Roncon-Albuquerque R, Marques J,
Leite-Moreira AF. Randomized controlled trial of remote ischaemic conditioning in
ST-elevation myocardial infarction as adjuvant to primary angioplasty (RIC-STEMI).
Basic Res Cardiol 2018;113:14.
26. Schjøtt J, Olsen H, Berg K, Jynge P. Pretreatment with ischaemia attenuates acute
epirubicin-induced cardiotoxicity in isolated rat hearts. Pharmacol Toxicol 1996;78:
381–386.
27. Maulik A, Davidson SM, Piotrowska I, Walker M, Yellon DM. Ischaemic precondition-
ing protects cardiomyocytes from anthracycline-induced toxicity via the PI3K path-
way. Cardiovasc Drugs Ther Cardiovascular Ther 2018;32:245–253.
28. Gertz ZM, Cain C, Kraskauskas D, Devarakonda T, Mauro AG, Thompson J,
Samidurai A, Chen Q, Gordon SW, Lesnefsky EJ, Das A, Salloum FN. Remote ische-
mic pre-conditioning attenuates adverse cardiac remodeling and mortality following
doxorubicin administration in mice. JACC CardioOncology 2019;1:221–234.
29. Chung R, Maulik A, Hamarneh A, Hochhauser D, Hausenloy DJ, Walker JM, Yellon
DM. Effect of remote ischaemic conditioning in oncology patients undergoing chemo-
therapy: rationale and design of the ERIC-ONC study - a single-center, blinded, ran-
domized controlled trial. Clin Cardiol 2016;39:72–82.
30. Jordan JH, Todd RM, Vasu S, Hundley WG. Cardiovascular magnetic resonance in
the oncology patient. JACC Cardiovasc Imaging 2018;11:1150–1172.
31. Kleinbongard P, Skyschally A, Heusch G. Cardioprotection by remote ischemic con-
ditioning and its signal transduction. Pflugers Arch - Eur J Physiol 2017;469:159–181.



























.32. Zhang S, Liu X, Bawa-Khalfe T, Lu L-S, Lyu YL, Liu LF, Yeh E. Identification of the mo-
lecular basis of doxorubicin-induced cardiotoxicity. Nat Med 2012;18:1639–1642.
33. Takemura G, Fujiwara H. Doxorubicin-induced cardiomyopathy. From the cardio-
toxic mechanisms to management. Prog Cardiovasc Dis 2007;49:330–352.
34. Koleini N, Kardami E. Autophagy and mitophagy in the context of doxorubicin-
induced cardiotoxicity. Oncotarget 2017;8:46663–46680.
35. Farhad H, Staziaki PV, Addison D, Coelho-Filho OR, Shah RV, Mitchell RN,
Szilveszter B, Abbasi SA, Kwong RY, Scherrer-Crosbie M, Hoffmann U, Jerosch-
Herold M, Neilan TG. Characterization of the changes in cardiac structure and func-
tion in mice treated with anthracyclines using serial cardiac magnetic resonance imag-
ing. Circ Cardiovasc Imaging 2016;9:e003584.
36. Przyklenk K, Dong Y, Undyala VV, Whittaker P. Autophagy as a therapeutic target
for ischaemia/reperfusion injury? Concepts, controversies, and challenges. Cardiovasc
Res 2012;94:197–205.
37. Roca-Agujetas V, Dios C, De Lestón L, Marı́ M, Morales A, Colell A. Recent insights
into the mitochondrial role in autophagy and its regulation by oxidative stress. Oxid
Med Cell Longev 2019;2019:1–16.
38. Christiansen S, Perez-Bouza A, Schälte G, Hilgers RD, Autschbach R. Selective left
ventricular adriamycin-induced cardiomyopathy in the pig. J Heart Lung Transplant
2008;27:86–92.
39. Goetzenich A, Hatam N, Zernecke A, Weber C, Czarnotta T, Autschbach R,
Christiansen S. Alteration of matrix metalloproteinases in selective left ventricular
adriamycin-induced cardiomyopathy in the pig. J Heart Lung Transpl 2009;28:
1087–1093.
40. Vleet J, Van LA G, Vj F. Pathologic features of adriamycin toxicosis in young pigs:
nonskeletal lesions. Am J Vet Res 1979;40:1537–1552.
41. Skyschally A, Gent S, Amanakis G, Schulte C, Kleinbongard P, Heusch G. Across-spe-
cies transfer of protection by remote ischemic preconditioning with species-specific
myocardial signal transduction by reperfusion injury salvage kinase and survival acti-
vating factor enhancement pathways. Circ Res 2015;117:279–288.
42. Kleinbongard P, Amanakis G, Skyschally A, Heusch G. Reflection of cardioprotection
by remote ischemic perconditioning in attenuated ST-segment elevation during ongo-
ing coronary occlusion in pigs evidence for cardioprotection from ischemic injury.
Circ Res 2018;122:1102–1108.
Translational perspective
Serial cardiac magnetic resonance (CMR) evaluation of a highly translatable large-animal model of anthracycline-induced cardiotoxicity (AIC) shows
that cumulative exposure to doxorubicin results in significantly reduced left ventricular ejection fraction (LVEF) and extensive mitochondrial fragmen-
tation. Remote ischaemic preconditioning (RIPC) applied before each doxorubicin cycle preserved cardiac contractility and LVEF in long-term CMR
exams. RIPC prevented doxorubicin-induced irreversible mitochondrial fragmentation and dysregulated autophagy. RIPC is as an attractive strategy
for testing in clinical trials in AIC.
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